403 related articles for article (PubMed ID: 28750804)
1. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
2. Binding Site Characterization of AM1336, a Novel Covalent Inverse Agonist at Human Cannabinoid 2 Receptor, Using Mass Spectrometric Analysis.
Mallipeddi S; Kreimer S; Zvonok N; Vemuri K; Karger BL; Ivanov AR; Makriyannis A
J Proteome Res; 2017 Jul; 16(7):2419-2428. PubMed ID: 28374590
[TBL] [Abstract][Full Text] [Related]
3. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose.
Zhou H; Peng Y; Halikhedkar A; Fan P; Janero DR; Thakur GA; Mercier RW; Sun X; Ma X; Makriyannis A
ACS Chem Neurosci; 2017 Jun; 8(6):1338-1347. PubMed ID: 28220706
[TBL] [Abstract][Full Text] [Related]
4. Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor.
Janero DR; Yaddanapudi S; Zvonok N; Subramanian KV; Shukla VG; Stahl E; Zhou L; Hurst D; Wager-Miller J; Bohn LM; Reggio PH; Mackie K; Makriyannis A
ACS Chem Neurosci; 2015 Aug; 6(8):1400-10. PubMed ID: 25978068
[TBL] [Abstract][Full Text] [Related]
5. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
[TBL] [Abstract][Full Text] [Related]
6. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
Janero DR; Thakur GA
Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
[TBL] [Abstract][Full Text] [Related]
7. Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis.
Porter RF; Szczesniak AM; Toguri JT; Gebremeskel S; Johnston B; Lehmann C; Fingerle J; Rothenhäusler B; Perret C; Rogers-Evans M; Kimbara A; Nettekoven M; Guba W; Grether U; Ullmer C; Kelly MEM
Molecules; 2019 Sep; 24(18):. PubMed ID: 31540271
[TBL] [Abstract][Full Text] [Related]
8. Highly Selective, Amine-Derived Cannabinoid Receptor 2 Probes.
Westphal MV; Sarott RC; Zirwes EA; Osterwald A; Guba W; Ullmer C; Grether U; Carreira EM
Chemistry; 2020 Jan; 26(6):1380-1387. PubMed ID: 31961047
[TBL] [Abstract][Full Text] [Related]
9. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.
Pei Y; Mercier RW; Anday JK; Thakur GA; Zvonok AM; Hurst D; Reggio PH; Janero DR; Makriyannis A
Chem Biol; 2008 Nov; 15(11):1207-19. PubMed ID: 19022181
[TBL] [Abstract][Full Text] [Related]
10. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
11. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
12. The bioisosteric concept applied to cannabinoid ligands.
Mugnaini C; Pasquini S; Corelli F
Curr Med Chem; 2012; 19(28):4794-815. PubMed ID: 22830341
[TBL] [Abstract][Full Text] [Related]
13. Indoles and related compounds as cannabinoid ligands.
Manera C; Tuccinardi T; Martinelli A
Mini Rev Med Chem; 2008 Apr; 8(4):370-87. PubMed ID: 18473928
[TBL] [Abstract][Full Text] [Related]
14. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches.
Reggio PH
Handb Exp Pharmacol; 2005; (168):247-81. PubMed ID: 16596777
[TBL] [Abstract][Full Text] [Related]
16. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation.
Szymanski DW; Papanastasiou M; Melchior K; Zvonok N; Mercier RW; Janero DR; Thakur GA; Cha S; Wu B; Karger B; Makriyannis A
J Proteome Res; 2011 Oct; 10(10):4789-98. PubMed ID: 21861534
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations.
Jung SW; Cho AE; Yu W
Sci Rep; 2018 Sep; 8(1):13787. PubMed ID: 30213978
[TBL] [Abstract][Full Text] [Related]
19. Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands.
Yang JF; Williams AH; Penthala NR; Prather PL; Crooks PA; Zhan CG
ACS Chem Neurosci; 2020 Oct; 11(20):3455-3463. PubMed ID: 32997485
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
